Menu

Speaking of Cancer Research

Notable quotes from this year’s annual meeting of the American Association for Cancer Research

Apr 5, 2017
Jef Akst

JEF AKST

“This is no time to undercut progress, for God’s sake. It’s no time to let up. It’s time to double down. It’s time we deliver on the promise of science and technology to extend and improve lives.”

—Former US Vice President Joe Biden

 

“Funding for cancer research isn’t something you can turn on and off like a faucet.”

Nancy Davidson, AACR President

 

“There has been a revolution in cancer research in the past decade. If I were to summarize that revolution in one sentence it would be: cancer results from the sequential accumulation of genomic alterations. . . . The challenge for all of us here to today is to achieve the next revolution, and that is to dramatically reduce deaths from cancer.”

Bert Vogelstein, Johns Hopkins Medicine

 

“At first blush, the problem of [cancer drug] resistance seems insurmountable. It’s multifactorial and heterogeneous. There can be multiple resistance mechanisms operating in a particular patient.”

Levi Garraway, Eli Lilly

 

“Early detection doesn’t have to be very early. . . . It takes years, perhaps decades, for a [malignancy] to evolve into a widely metastatic lesion, offering a huge window of opportunity to detect those cancers and intervene in the process.”

Vogelstein

 

“In our fight against cancer, we have to be unwilling to postpone for even a second. . . . Let’s keep it going, folks. This is no time to stop the momentum.”

Biden

April 2019

Will Car T Cells Smash Tumors?

New trials take the therapy beyond the blood

Marketplace

Sponsored Product Updates

Myth Busting: The Best Way to Use Pure Water in the Lab
Myth Busting: The Best Way to Use Pure Water in the Lab
Download this white paper from ELGA LabWater to learn about the role of pure water in the laboratory and the advantages of in-house water purification!
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu's New Nexera UHPLC Series with AI and IoT Enhancements Sets Industry Standard for Intelligence, Efficiency and Design
Shimadzu Corporation announces the release of the Nexera Ultra High-Performance Liquid Chromatograph series, incorporating artificial intelligence as Analytical Intelligence, allowing systems to detect and resolve issues automatically. The Nexera series makes lab management simple by integrating IoT and device networking, enabling users to easily review instrument status, optimize resource allocation, and achieve higher throughput.
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
IDT lowers genomic barriers with powerful rhAmpSeq™ targeted sequencing system
Increasing accuracy and reducing cost barriers, IDT’s innovative system delivers simple and cost-effective amplicon sequencing
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Introduces Isotype-Specific Secondary Antibodies
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.